Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic ...

BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. LifeSci Capital is acting as lead manager and H.C.

With chronic kidney disease projected to be the fifth leading cause of death by 2040, Nephrologist Dr. Adrian Sawyer is ...

BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. LifeSci Capital is acting as lead manager and H.C.

Mineralys’ shares got a more than 50% boost Monday morning as new data showed its hypertension drug reduced blood pressure in ...

HALF a million Brits with deadly high blood pressure could be cured by a transformative new treatment. Doctors from the UK ...

The US FDA has approved scPharmaceuticals’ sNDA for Furoscix, expanding its indication to include oedema treatment in ...

Addison’s disease is a rare condition in which the adrenal glands do not produce enough of the hormones cortisol and ...

Medically reviewed by Mary Choy, PharmD It can be surprising to learn that a medication you’re taking for one condition may ...